Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects
Authors:
- E. G. KamkinEKE. G. Kamkin
- E. V. KarakulinaEKE. V. Karakulina
- E. M. AstapenkoEAE. M. Astapenko
- V. A. GulshinaVGV. A. Gulshina
- A. A. MoskalevAMA. A. Moskalev
- A. S. StarovoytovaASA. S. Starovoytova
- E. P. MazygulaEME. P. Mazygula
- Z. N. TautovaZTZ. N. Tautova
- N. E. ZvartauNZN. E. Zvartau
- E. A. MedvedevaE. A. Medvedeva
- A. E. SolovievaASA. E. Solovieva
- K. A. ZagorodnikovaKZK. A. Zagorodnikova
Open Access
- 8 August 2025
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6391
Abstract
A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.Keywords
This publication has 31 references indexed in Scilit:
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Statins for secondary prevention and major adverse events after coronary artery bypass graftingThe Journal of Thoracic and Cardiovascular Surgery, 2022
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection FractionJACC: Heart Failure, 2022
- Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD TherapyJACC: Clinical Electrophysiology, 2021
- Medication adherence and its determinants in patients after myocardial infarctionScientific Reports, 2020
- Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort studyThe Lancet, 2020
- Association of Medicaid Expansion With Cardiovascular MortalityJAMA Cardiology, 2019
- Assessing the Impact of Medication Adherence on Long-Term Cardiovascular OutcomesJACC, 2016
- Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarctionEuropean Heart Journal - Quality of Care and Clinical Outcomes, 2016
- Impact of Aspirin and Statins on Long-Term Survival in Patients Hospitalized with Acute Myocardial Infarction Complicated by Heart Failure: An Analysis of 1706 PatientsEuropean Journal of Heart Failure, 2013